NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球樹突狀細胞疫苗市場(2020年∼2027年)

Global Dendritic Cell Cancer Vaccines Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1004517
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
全球樹突狀細胞疫苗市場(2020年∼2027年) Global Dendritic Cell Cancer Vaccines Market - 2020-2027
出版日期: 2021年05月10日內容資訊: 英文 180 Pages
簡介

越來越多的癌症患者正在推動全球樹突狀細胞疫苗市場的增長。對治療的需求增加、抗癌藥物的創新、技術改進、癌症治療意識的提高以及醫療成本的增加預計將推動市場增長。

本報告提供全球樹突狀細胞疫苗市場調查市場調查,彙整市場概要,市場區隔·各地區的市場規模及成長率的變化與預測,新型冠狀病毒感染疾病(COVID-19)的影響分析,市場成長的推動要素及阻礙因素分析,市場機會,價格及貿易趨勢,競爭情形,主要企業簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 市場定義和概要

第3章 摘要整理

  • 市場明細:各產品類型
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 市場動態

  • 市場影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求
  • 專利趨勢

第6章 新型冠狀病毒感染疾病(COVID-19)的影響分析

  • 新型冠狀病毒感染疾病(COVID-19)的影響分析
    • COVID-19前的市場方案
    • 目前市場方案
    • COVID-19後的市場方案
  • COVID-19疫情下價格趨勢
  • 供需頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 總論

第7章 全球樹突狀細胞疫苗市場:各產品類型

  • 簡介
  • 市場規模·與前一年同期比較成長率分析:各產品類型
  • 市場魅力指數:各產品類型
    • Provenge(Sipuleucel-T)
    • Apceden
    • CreaVax
    • 其他

第8章 全球樹突狀細胞疫苗市場:各終端用戶

  • 簡介
  • 市場規模·與前一年同期比較成長率分析:各終端用戶
  • 市場魅力指數:各終端用戶
    • 大人
    • 兒童
    • 其他

第9章 全球樹突狀細胞疫苗療法市場:各地區

  • 簡介
  • 市場規模分析·與前一年同期比較成長率:各地區
  • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各產品類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 歐洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各產品類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 南美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各產品類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 亞太地區
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各產品類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 中東·非洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各產品類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國

第10章 競爭情形

  • 競爭模式
  • 市場定位/股票分析
  • 合併·收購分析

第11章 企業簡介

  • Biffa Group
    • 企業概要
    • 產品系列
    • 主要的焦點
    • 財務形勢
  • 3M Company
  • Activarti
  • Argos Therapeutics
  • Bellicum Pharmaceuticals
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Medigene
  • Merck & Co
  • Northwest Biotherapeutics

第12章 重要考察

第13章 關於DataM Intelligence

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global dendritic cell cancer vaccines market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Cancer treatment vaccines are made up of cancer cells, parts of cancer cells or antigens. These are made to recognize proteins on specific cancer cells. These cells help the immune system to recognize and attack those cancer cells. These vaccines might eventually help stop cancer growth, prevent cancer from coming back, and destroy cancer cells left behind after other treatments. Monocytes are extracted from the bloodstream of patients and cultured with synthetic forms of selected cancer neoantigens to form mature dendritic cells carrying those neoantigens. These cells are then reinfused into the patient's blood circulation. These dendritic cells help the immune system to recognize and attack abnormal cells, such as cancer cells. To make the vaccine, scientists grow dendritic cells alongside cancer cells in the lab. The vaccine then stimulates the immune system to attack cancer.

Market Dynamics

The growing incidence of cancer cases drives the global dendritic cell cancer vaccines market growth, increasing demand for therapies, improving technology such as drug innovations regarding cancer, upsurge in awareness about cancer and their available therapies, and increasing health care expenditure drive the market.

Growing incidence of cancer cases globally, is expected to drive the global Dendritic Cell Cancer Vaccines market growth.

As per the World Health Organization (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. This number has led to an increase in the adoption of various cancer vaccines.

Stringent regulatory procedures are likely restricting the market growth.

As the increase in innovative strategies with novel products, a 2-way dialog with regulators is recommended on a case-by-case basis to justify the clinical development plan, taking into account specific quality issues related to the product's development. The rationale, background and justification for the planned development must be convincing when interacting with the regulatory authorities to enable drug developers and regulators to reach an agreement.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the Personalized Cancer Vaccines. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

Based on the Product Type, the global dendritic cell cancer vaccines market is segmented into Provenge (Sipuleucel-T), Apceden, CreaVax and Others

Provenge (Sipuleucel-T) accounts the largest share of the market.

Provenge (Sipuleucel-T) is a first approved dendritic cell cancer vaccine used to treat metastatic prostate cancer. It is used in patients with few or no symptoms and whose cancer is castration-resistant. It is made from a patient's immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Sipuleucel-T helps the immune system to kill prostate cancer cells, is a type of cellular adoptive immunotherapy. Also called APC8015 and Provenge. For instance, Sipuleucel-T was approved by the FDA on April 29, 2010, for the treatment of asymptomatic or less symptomatic metastatic castrate-resistant prostate cancer developed by Dendreon Corporation.

Based on End-users, the global Dendritic Cell Cancer Vaccines market is segmented into Pediatrics, Adults and Others

Dendritic cell vaccine treatment has been performed targeting many different types of tumor entities, most of which belong to types of cancer typically occurring in adults like melanoma, renal cell carcinoma, breast, colon, and prostate cancer, and Malignant glioma has also gained considerable attention in the field. This tumor is a tumor entity relevant also in pediatric oncology.

Geographical Analysis

North America region holds the largest market share global Dendritic Cell Cancer Vaccines market

North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Capital Medical University Collaborated with Duke University conducting early Phase 1 study on personalized vaccine generated by Autologous Dendritic Cells Pulsed with Autologous Whole Tumor Cell Lysate to treat Advanced Solid Tumor Patients.

Competitive Landscape

The Global Dendritic Cell Cancer Vaccines Market is quite competitive with some key competitors like 3M Company, Activarti, Argos Therapeutics, Bellicum Pharmaceuticals, Dendreon Corporation, Elios Therapeutics. ImmunoCellular Therapeutics, Medigene, Merck & co, Northwest Biotherapeutics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, On June 2, 2020, Northwest Biotherapeutics Inc, developed DCVax personalized immune therapy for solid tumor cancers is under Phase I/II trial of DCVax-Direct for all types of inoperable solid tumors.

Dendreon Corporation

Overview: Dendreon is a biotechnology company headquartered in California. Its lead product, Provenge, known generically as sipuleucel-T, is immunotherapy for prostate cancer and consists of a mixture of the patient's blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. In 2017, Dendreon resumed operations as a standalone company following an acquisition by Sanpower Group for $819.9 million.

Product Portfolio: Dendreon aims to stay at the forefront of development, manufacturing, and commercialization of immunotherapies that harness the power of the body's immune system to help extend patients' lives.

Key developments: P11-3 (STAMP)- A randomized, open-label, Phase 2 Trial of sipuleucel-T with concurrent versus sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer (mCRPC).

Why Purchase the Report?

  • Visualize the composition of the Dendritic Cell Cancer Vaccines Market segmentation by Product type, End-users, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in Dendritic Cell Cancer Vaccines Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Dendritic Cell Cancer Vaccines Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Dendritic Cell Cancer Vaccines Market report would provide an access to an approx. 53 market data table, 43 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Dendritic Cell Cancer Vaccines Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Dendritic Cell Cancer Vaccines Market - Market Definition and Overview

3. Global Dendritic Cell Cancer Vaccines Market- Executive Summary

  • 3.1. Market snippet by Product Type
  • 3.2. Market Snippet by End-users
  • 3.3. Market Snippet by Region

4. Global Dendritic Cell Cancer Vaccines Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of Cancer cases
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent regulatory procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Dendritic Cell Cancer Vaccines Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Dendritic Cell Cancer Vaccines Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Dendritic Cell Cancer Vaccines Market - By Product type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
  • 7.3. Market Attractiveness Index, By Product type
    • 7.3.1. Provenge (Sipuleucel-T) *
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Apceden
    • 7.3.3. CreaVax
    • 7.3.4. Others

8. Global Dendritic Cell Cancer Vaccines Market - By End-users

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment
  • 8.3. Market Attractiveness Index, By End-users Segment
    • 8.3.1. Adults*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Pediatrics
    • 8.3.3. Others

9. Global Dendritic Cell Cancer Vaccines Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Global Dendritic Cell Cancer Vaccines Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Dendritic Cell Cancer Vaccines Market - Company Profiles

  • 11.1. Dendreon Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. 3M Company,
  • 11.3. Activarti,
  • 11.4. Argos Therapeutics,
  • 11.5. Bellicum Pharmaceuticals,
  • 11.6. Elios Therapeutics.
  • 11.7. ImmunoCellular Therapeutics,
  • 11.8. Medigene,
  • 11.9. Merck & Co,
  • 11.10. Northwest Biotherapeutics

LIST NOT EXHAUSTIVE

12. Global Dendritic Cell Cancer Vaccines Market - Premium Insights

13. Global Dendritic Cell Cancer Vaccines Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us